Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo BID

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    454 result(s) found for: placebo BID. Displaying page 1 of 23.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000383-27 Sponsor Protocol Number: D1803C00002 Start Date*: 2004-07-28
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowe...
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003484-36 Sponsor Protocol Number: MP1032-CT04 Start Date*: 2018-01-19
    Sponsor Name:MetrioPharm AG
    Full Title: A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Study of Two Oral Doses (150 mg bid / 300 mg bid) of MP1032 in Male and Female Patients with Moderate-to-Severe Chroni...
    Medical condition: chronic Psoriasis Plaque moderate-to-severe
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003723-29 Sponsor Protocol Number: JBT101-CF-002 Start Date*: 2018-05-11
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Medical condition: Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000078-21 Sponsor Protocol Number: HCT 3012-X-303 Start Date*: 2007-10-11
    Sponsor Name:NicOx S.A
    Full Title: A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo bid and Naproxen 500 mg bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HC...
    Medical condition: Osteoarthritis of the Hip
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed) BG (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004722-16 Sponsor Protocol Number: CLAF237B2224 Start Date*: 2009-03-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) IT (Completed) FI (Completed) SK (Completed) DE (Completed) AT (Completed) LT (Completed) SE (Completed) LV (Completed) BE (Completed) DK (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001248-30 Sponsor Protocol Number: XRP1526B/3031 Ciclesidone Start Date*: 2006-06-16
    Sponsor Name:Sanofi-Aventis U.S. Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-...
    Medical condition: Asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging. The inflammatory compon...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007338-23 Sponsor Protocol Number: CLCI699A2216 Start Date*: 2009-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks...
    Medical condition: resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2010-020794-16 Sponsor Protocol Number: BUSAL-II-10-2 Start Date*: 2010-10-15
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase II, randomised, partially-blinded, cross over study to evaluate the systemic effect of two doses of the SMB BUDESONIDE-SALMETEROL DPI fixed-dose combination capsule (300/25 µg BID and 150/2...
    Medical condition: Patients with a mild persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001555-37 Sponsor Protocol Number: CC-10004-AS-001 Start Date*: 2012-09-04
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyl...
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SK (Completed) NL (Completed) ES (Completed) PL (Completed) SE (Completed) CZ (Completed) AT (Completed) BG (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001250-24 Sponsor Protocol Number: 850 1016-1562 Start Date*: 2005-08-16
    Sponsor Name:APOGEPHA Arzneimittel GmbH
    Full Title: Proof-of-Concept Trial of NS-8 in 3 doses: Comparison of efficacy and tolerability in patients with overactive bladder.
    Medical condition: Subjects with overactive bladder syndrome with urinary urge.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003412-59 Sponsor Protocol Number: CCD-0704-PR-0024 Start Date*: 2007-08-22
    Sponsor Name:Chiesi Farmaceutici S.p.A
    Full Title: A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 µg ...
    Medical condition: Mild asthma in children (males and females) 6-14 years
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049585 Infantile asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001546-32 Sponsor Protocol Number: CLAF237A2305 Start Date*: 2004-09-07
    Sponsor Name:Novartis Finland Oy
    Full Title: A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with ...
    Medical condition: Patients with type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005146-39 Sponsor Protocol Number: P04501 Start Date*: 2006-09-14
    Sponsor Name:Schering Plough Research Institute
    Full Title: A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Su...
    Medical condition: Moderate to severe Parkinson s disease with motor fluctuation and dyskinesias.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000789-11 Sponsor Protocol Number: EL110006 Start Date*: 2005-01-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 12-week, randomised, double-blind, placebo-controlled, parallel-group multicentre study to evaluate the anti-inflammatory activity of GW842470 4mg twice daily on pulmonary hyperinflation in patie...
    Medical condition: Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD) - Stage II or III
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023326-20 Sponsor Protocol Number: 1268.17 Start Date*: 2010-12-29
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A randomized, double blind, placebo and active controlled, parallel group study to evaluate the safety and efficacy of 6-week treatment with oral doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b....
    Medical condition: Mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021097-11 Sponsor Protocol Number: CLAF237A23152 Start Date*: 2010-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri...
    Medical condition: Type II Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023992-24 Sponsor Protocol Number: MEMAP1 Start Date*: 2011-08-26
    Sponsor Name:University of Leipzig
    Full Title: International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
    Medical condition: acute mania and hypomania (ICD-10: F30.0, F30.1, F31.0, F31.1)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10000852 Acute mania LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-001539-30 Sponsor Protocol Number: C21013 Start Date*: 2012-09-27
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer
    Medical condition: progressive castration-resistant prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed) GR (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006062-36 Sponsor Protocol Number: NW-3509/008A/II/2020 Start Date*: 2021-06-30
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...
    Medical condition: Chronic schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) HU (Completed) PL (Completed) EE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001187-52 Sponsor Protocol Number: AX.- CL – 06a Start Date*: 2004-11-12
    Sponsor Name:Axonyx Corporation
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Two Different Dosages of Phenserine-tartrate in Patients with Mild to Moderate Probable Alzheimer’s Disea...
    Medical condition: Alzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking. In addition to the cognitive d...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001896 Prim
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 09:56:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA